Tesamorelin 5mg
Tesamorelin (5 mg) is a synthetic analogue of growth hormone–releasing hormone (GHRH), developed to model the stimulation of endogenous growth hormone (GH) production. It is widely studied in metabolic and endocrine research for its effects on body composition, visceral fat reduction, and lean-mass preservation. By acting on pituitary GHRH receptors, Tesamorelin enhances physiologic GH pulsatility while maintaining feedback sensitivity.
Key Research Features
- Compound: Tesamorelin (GHRH 1-44 analogue)
- Class: Growth hormone secretagogue analogue
- Form: Lyophilized peptide powder for reconstitution
- Concentration: 5 mg per vial
- Primary Focus: GH release modeling, lipolysis, lean-mass maintenance
Quickstart Highlights
- Typical daily range: 1 – 2 mg (Mon – Fri)
- Injection type: Subcutaneous (preferred in fasted state, morning)
- Reconstitution: Add 1 mL bacteriostatic water → 5 mg/mL concentration
- Storage: Reconstituted = refrigerated (2–8 °C)
- Weekend washout: Two consecutive off-days per week to maintain receptor sensitivity
Dosing & Reconstitution Guide (Educational)
Standard / Gradual Protocol — 1 mL = 5 mg/mL
| Weeks | Daily Reference Dose | Insulin-Syringe Units |
|---|---|---|
| 1 – 4 | 1 mg (5 days / week) | 20 units (0.20 mL) |
| 5 – 8 | 1 mg (5 days / week) | 20 units (0.20 mL) |
- Draw 1 mL bacteriostatic water into a sterile syringe.
- Inject slowly down the vial wall to prevent foaming.
- Swirl gently until dissolved — avoid shaking.
- Label with reconstitution date; store at 2–8 °C.
Advanced / Aggressive Protocol — 1 mL = 5 mg/mL
| Weeks | Daily Reference Dose | Insulin-Syringe Units |
|---|---|---|
| 1 – 4 | 2 mg (5 days / week) | 40 units (0.40 mL) |
| 5 – 8 | 2 mg (5 days / week) | 40 units (0.40 mL) |
Note: At 2 mg/day, one 5 mg vial provides approximately 2–3 days’ supply; multiple vials per week may be required for complete cycles.
Protocol Overview
- Goal: Evaluate endogenous GH release and body-composition response
- Schedule: Subcutaneous injection once daily (Mon – Fri)
- Cycle length: 8 – 16 weeks
- Washout: 2 off-days weekly to sustain receptor activity
- Dose range: 1 – 2 mg/day (5 – 10 mg/week)
- Timing: Morning, fasted state preferred
Expected Research Observations
- Elevated plasma GH and IGF-1 concentrations (transient pulse-type response)
- Improved lean-mass-to-fat ratio in controlled models
- Reduction in visceral-adipose accumulation
- Preserved insulin sensitivity compared with exogenous GH models
Outcomes based on pre-clinical and controlled human research models; not indicative of therapeutic results.
Storage & Handling
- Lyophilized: Store in a cool dark place
- Reconstituted: Refrigerate (2–8 °C), protected from light; use within 30 days.
- Do not freeze after reconstitution.
What’s in the Box
- 1 × Tesamorelin 5 mg lyophilized vial
- 1 × 2 mL bacteriostatic water vial for reconstitution
Why Choose EU Pharmaceuticals?
EU Pharmaceuticals peptides are manufactured to research-grade standards and independently verified by HPLC and Mass Spectrometry. Each vial provides consistent purity and concentration, supporting reliable data generation for endocrine and metabolic-function research.
For laboratory, educational, and research use only. Not for human or veterinary ingestion or therapeutic application. No medical or performance claims are made or implied. Buyer assumes responsibility for lawful handling and regulatory compliance.
